2nd Firdapse Patent Secured in US by Catalyst with 3 Still Pending

2nd Firdapse Patent Secured in US by Catalyst with 3 Still Pending

299981

2nd Firdapse Patent Secured in US by Catalyst with 3 Still Pending

Catalyst Pharmaceuticals has secured a second U.S. patent covering Firdapse (amifampridine), an approved oral treatment for Lambert-Eaton myasthenic syndrome (LEMS). “We are pleased that this second patent for Firdapse has been issued and believe that it further enhances our intellectual property protection for Firdapse,” Patrick J. McEnany, chairman and CEO of Catalyst, said in a press release. Recommended Reading November 30, 2020 by Brian Murphy Ph.D. FAQs About Firdapse as Treatment for LEMS Catalyst secured…

You must be logged in to read/download the full post.